ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0911

A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
Abstract Number: 2204

A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications
Abstract Number: 0946

A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Abstract Number: 2155

A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency
Abstract Number: 2011

A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
Abstract Number: 0277

A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Abstract Number: 1674

A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
Abstract Number: 2012

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
Abstract Number: 0473

A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Abstract Number: 1172

A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease
Abstract Number: 2181

A Pilot High-Fidelity Simulation for Pediatric Rheumatology Learners
Abstract Number: 2247

A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array
Abstract Number: 1731

A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
Abstract Number: 2371

A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
Abstract Number: 0303

A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].